New York, May 03, 2024 - PRISM MarketView - AIM ImmunoTech’s (NYSE American: AIM) combination therapy for the treatment of late-stage pancreatic cancer has demonstrated safety and tolerability in a Phase 1b/2 study being conducted by the company in the Netherlands. No treatment-related severe adverse events or dose-limiting toxicities were noted by investigators at the Erasmus Medical Center, which is collaborating with AIM on the study.
AIM stated that the safety data was an essential step forward in testing the combination of its Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in pancreatic cancer patients.
Based on the results, AIM expects to escalate to the next dose and will begin dosing the next cohort of patients imminently. Subjects enrolled in the study will continue treatment for 48 weeks.
AIM’s market cap stands at $20.51 million and the company has generated a growing body of promising data demonstrating its lead candidate, Ampligen’s potential to address multiple high-value indications.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Vaxart, Inc. (Nasdaq: VXRT) is listed on PRISM Emerging Biotech Index
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to monitoring and analyzing small-cap stocks in emerging sectors. We offer up-to-the-minute financial news, provide comprehensive investment tools, and foster a dynamic community of investors. Central to our offerings are proprietary indices that track emerging sectors, including biotechnology, clean energy, next-generation technology, medical devices, and more. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or authorized broker-dealer or investment advisor and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
PRISM MarketView
646-863-6341
Prism MarketView | Stock Market News and Investment Opportunities
PRISM MarketView - Social Media (X)